ProCE Banner Series

Tissue Is Not Always the Issue: Expanding Armamentarium of Histology-Agnostic Targeted Therapies

Join us in Chicago or via simulcast for this live, interactive, CME-certified Master Class symposium featuring expert-led presentations and small group patient case discussions on the optimal assessment of histology-agnostic biomarkers and their impact on therapeutic planning across multiple tumor types.

To Register: Please click the green “Learn More” button below. On the next page, select either Register for In-Person Event or Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

For more information on ASCO’s Health and Safety policy for this event, please visit ASCO’s website.

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.

  AMA
Who Should Attend

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with cancer.

All Events

Tissue Is Not Always the Issue: Expanding Armamentarium of Histology-Agnostic Targeted Therapies

Past Events

June

02

2023

7:00 PM - 9:00 PM Central Time (CT)

In-personVirtual

Hilton Chicago, 720 South Michigan Avenue, Chicago, Illinois 60604

Faculty

ProCE Banner Faculty
Nagla Abdel Karim, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
University of Virginia
Director of Early Therapeutics Program/Phase I Program
Inova Schar Cancer Institute
Fairfax, Virginia

ProCE Banner Faculty
Chul Kim, MD, MPH

Associate Professor
Department of Medicine, Division of Hematology and Oncology
Georgetown Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

ProCE Banner Faculty
John Marshall, MD

Executive Director 
Medstar Hematology/Oncology
Director
Ruesch Center for Cure of GI Cancers
Lombardi Comprehensive Cancer Center Georgetown University
Washington, DC

ProCE Banner Faculty
Sapna P. Patel, MD

Chair, SWOG Melanoma Committee
SWOG Cancer Research Network
Associate Professor, Director of the Uveal Melanoma Program
The University of Texas MD Anderson Cancer Center
Houston, Texas

ProCE Banner Faculty
Neil H. Segal, MD, PhD

Research Director
Associate Attending, Gastrointestinal Oncology Service
Division of Gastrointestinal Oncology
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
Cornell University
New York, New York

ProCE Banner Faculty
Jonathan Trent, MD, PhD

Professor of Medicine
Department of Medical Oncology
Miller School of Medicine
Sylvester Comprehensive Cancer Center
Miami, Florida

Topics

  • Welcome and Introduction
  • Histology-Agnostic Biomarker Assessment and Impact on Therapeutic Planning
  • Master Class Interactive Case Discussion
  • Histology-Agnostic Biomarkers and Approved Targeted Therapies: BRAF V600E mutations, RET fusions, NTRK fusions
  • Master Class Interactive Case Discussion
  • Histology-Agnostic Biomarkers and Approved Immunotherapy: TMB-H, MSI-H/dMMR
  • Master Class Interactive Case Discussion
  • Future Directions in Histology-Agnostic Therapies
  • Final Panel Discussion and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to apply practice-changing clinical data and expert recommendations to optimally integrate histology-agnostic therapies into treatment of eligible patients with cancer. 

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions, mutations, and other targetable genomic alterations in patients with malignant solid tumors
  • Appraise emerging clinical efficacy and safety data supporting the use of histology-agnostic therapies in solid tumors
  • Formulate strategies for integrating histology-agnostic agents into the management of eligible patients with cancer based on biomarker assessment, current evidence as well as expert and guideline recommendations
  • Identify and refer eligible patients with appropriate biomarkers for enrollment in ongoing clinical trials investigating histology-agnostic therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from Aadi Bioscience, Bayer HealthCare Pharmaceuticals Inc., and Lilly.